Albert Hagelgans

Albert Hagelgans

Auto-generated profile, based on publicly available information

Albert Hagelgans

Institute of Clinical Chemistry and Laboratory Medicine, University Hospital `Carl Gustav Carus`, Technical University of Dresden, Dresden 01307, Germany

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1997 in Cell Calcium
Verified
Journal Article
Closed access
MZMaria Zamaraeva
Maria Zamaraeva
AHAlbert I. Hagelgans
Albert I. Hagelgans
AAANDREY Abramov
ANDREY Abramov
VTVadim I. Ternovsky
Vadim I. Ternovsky
PMPetr Merzlyak
Petr Merzlyak
ASAshraf I. Saldkhodzjaev
Ashraf I. Saldkhodzjaev

1 May 2001 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
AAANDREY Abramov
ANDREY Abramov
MZMaria Zamaraeva
Maria Zamaraeva
AHAlbert I Hagelgans
Albert I Hagelgans
RARustam R Azimov
Rustam R Azimov
OKOleg V Krasilnikov
Oleg V Krasilnikov

5 December 2012 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MMMario Menschikowski
Mario Menschikowski
UPUwe Platzbecker
Uwe Platzbecker
AHAlbert Hagelgans
Albert Hagelgans
MVMargot Vogel
Margot Vogel
CTChristian Thiede
Christian Thiede
GSGabriele Siegert
Gabriele Siegert
The M-type phospholipase A2 receptor (PLA2R1) plays a crucial role in several signaling pathways and may act as tumor-suppressor. This study examined the expression and methylation of the PLA2R1 gene in Jurkat and U937 leukemic cell lines and its methylation in patients with myelodysplastic syndrome (MDS) or acute leukemia.

7 August 2023 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
DPDilipkumar Pal
Dilipkumar Pal
PSPooja Sahu
Pooja Sahu
AMAbhishek K. Mishra
Abhishek K. Mishra
AHAlbert Hagelgans
Albert Hagelgans
Olga SukochevaOlga Sukocheva
Olga Sukocheva
Background: Epigenetic regulation of gene signalling is one of the fundamental molecu-lar mechanisms for the generation and maintenance of cellular memory. Histone acetylation is a common epigenetic mechanism associated with increased gene transcription in the central nervous system (CNS). Stimulation of gene transcription by histone acetylation is important for the devel-opment of CNS-based long-term memory. Histone acetylation is a target for cognitive enhancement via the application of histone deacetylase (HDAC) inhibitors. The promising potential of HDAC in-hibitors has been observed in the treatment of several neurodevelopmental and neurodegenerative diseases. Objective: This study assessed the current state of HDAC inhibition as an approach to cognitive en-hancement and treatment of neurodegenerative diseases. Our analysis provides insights into the mechanism of action of HDAC inhibitors, associated epigenetic priming, and describes the thera-peutic success and potential complications after unsupervised use of the inhibitors. Results and Conclusion: Several chromatin-modifying enzymes play key roles in the regulation of cognitive processes. The importance of HDAC signaling in the brain is highlighted in this review. Recent advancements in the field of cognitive epigenetics are supported by the successful develop-ment of various HDAC inhibitors, demonstrating effective treatment of mood-associated disorders. The current review discusses the therapeutic potential of HDAC inhibition and observed complica-tions after mood and cognitive enhancement therapies.

1 June 2013 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
AHAlbert Hagelgans
Albert Hagelgans
MMMario Menschikowski
Mario Menschikowski
SFSusanne Fuessel
Susanne Fuessel
BNBrit Nacke
Brit Nacke
BABorros M. Arneth
Borros M. Arneth
GSGabriele Siegert
Gabriele Siegert

3 December 2017 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
AHAlbert Hagelgans
Albert Hagelgans
CJCarsten Jandeck
Carsten Jandeck
MFMarkus Friedemann
Markus Friedemann
ADAnastasia Donchin
Anastasia Donchin
SRSusan Richter
Susan Richter
MMMario Menschikowski
Mario Menschikowski
Background/Aim: To date there has been no investigation into the epigenetic regulation of the serine protease inhibitor SERPINA5 in prostate cancer, where lack of this gene was considered to facilitate invasive growth patterns. Materials and Methods: Methylation degrees of eight CpG sites of SERPINA5 were analyzed in normal and malignant prostate cells using nucleotide sequencing, methylation-specific high resolution melting and digital droplet PCR techniques. Results: The methylation degree of five CpG sites significantly correlated with lower SERPINA5 expression levels. In contrast, two CpG sites (at -19 bp and -14 bp from the transcription start site) were hypermethylated in normal epithelial prostate cells, benign hyperplasic cells and low-invasive malignant LNCaP cells, whereas in aggressive DU-145 and PC-3 cell lines, these sites were essentially unmethylated. Conclusion: Novel methylation patterns of two distinct CpG sites of the SERPINA5 promoter may be useful for differentiating benign from malignant prostate disease.